Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$113.95 USD

113.95
75,481

+0.09 (0.08%)

Updated Oct 8, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

by Zacks Equity Research

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why AstraZeneca (AZN) is Outperforming Its Industry

by Zacks Equity Research

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Incyte Treats First Patient in Phase III Vitiligo Study

by Zacks Equity Research

Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.

Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy

by Zacks Equity Research

Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex

Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval

by Zacks Equity Research

Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates

by Kinjel Shah

FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

by Zacks Equity Research

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

Novartis Announces New Data on Spondylitis Drug Cosentyx

by Zacks Equity Research

Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis

by Zacks Equity Research

J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.

Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

by Zacks Equity Research

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

Is Novartis (NVS) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Biogen Stops Late-Stage Studies on Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.

Kinjel Shah headshot

Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

by Kinjel Shah

The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.

Adverum Reports Data From Phase I Wet AMD Study, Stock Down

by Zacks Equity Research

Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.

J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

by Zacks Equity Research

J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

4 Big Drugmakers Boasting Impressive Oncology Pipelines

by Kinjel Shah

We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

by Zacks Equity Research

The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

Novartis Announces Positive Long-Term Data on Migraine Drug

by Zacks Equity Research

Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?

by Zacks Equity Research

Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.

FDA Grants Priority Review to Global Blood's SCD Candidate

by Zacks Equity Research

The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.

Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA

by Zacks Equity Research

The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

by Kinjel Shah

Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.